Disabling autophagy as a treatment for lysosomal storage diseases
Inventors
Raben, Nina N. • Schreiner, Cynthia • Baum, Rebecca • Takikita, Shoichi • Xie, Tao • Plotz, Paul H.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided herein are methods of treating lysosomal storage disease, for instance Pompe disease, through inhibition of autophagy. Optionally, treatment is administered as an adjunct to enzyme replacement therapy (ERT).
Core Innovation
The invention provides methods of treating lysosomal storage disorders, exemplified by Pompe disease, through inhibition of autophagy. Treatment can be administered as an adjunct to enzyme replacement therapy (ERT). This approach involves selecting a subject with a lysosomal storage disorder and administering a therapeutically effective amount of an agent that inhibits autophagy, thereby treating the disorder.
Lysosomal storage disorders result from partial or complete deficiency of lysosomal hydrolases, leading to incomplete lysosomal digestion and accumulation of undigested substrates, causing progressive neuro- and muscular degeneration. Pompe disease, a lysosomal storage disorder caused by deficiency of lysosomal acid α-glucosidase (GAA), leads to glycogen accumulation primarily in skeletal and cardiac muscle. Current ERT effectively clears glycogen in cardiac muscle but is less effective in skeletal muscle, necessitating improved treatment approaches.
Autophagy is a conserved cellular degradation mechanism involving the sequestration of cytosolic components into autophagosomes that fuse with lysosomes. The invention surprisingly discovers that inhibition of autophagy is an effective therapy and adjunctive therapy for Pompe disease and other lysosomal storage disorders. Agents inhibiting autophagy include oligonucleotides, morpholinos, shRNAs targeting essential autophagy genes (such as Atg5 or Atg7), inhibitors of class III PI3 kinase, and combinations thereof, optionally administered intramuscularly. The inhibition of autophagy facilitates enhanced glycogen clearance in skeletal muscle and improves ERT efficacy.
Claims Coverage
The claims include one independent claim detailing a method of treating Pompe disease by administering an antisense compound to inhibit Atg5 or Atg7 expression in a subject undergoing enzyme replacement therapy, with further dependent claims specifying administration details and agent types.
Use of antisense compounds to inhibit autophagy genes during ERT
A method to treat Pompe disease in subjects undergoing enzyme replacement therapy by administering a therapeutically effective amount of an antisense compound that inhibits expression of essential autophagy genes Atg5 or Atg7.
Intramuscular administration and skeletal muscle targeting
The antisense compound is administered intramuscularly and inhibits expression of Atg5 or Atg7 specifically in skeletal muscle.
Types of antisense compounds used for inhibition
Administration of oligonucleotides, morpholino oligonucleotides, or shRNAs of at least 15 bases that hybridize under high stringency conditions to mRNAs encoding Atg5 or Atg7, singly or in combination, including shRNA expressed from plasmids and sequences exemplified by SEQ ID NO: 16.
Inclusion of detectable labels and sequence complementarity
The antisense compound may comprise a detectable label, and the oligonucleotide, morpholino, or shRNA exhibits at least 80% complementarity to the target mRNA encoding an essential autophagy gene.
Use of morpholino oligonucleotides conjugated to cell-penetrating peptides
Treatment via administration of morpholino oligonucleotides of at least 15 bases that hybridize to mRNAs encoding Atg5 or Atg7, conjugated to cell-penetrating peptides, which inhibit expression of these essential autophagy genes.
The claims focus on methods of treating Pompe disease in subjects undergoing enzyme replacement therapy by inhibiting expression of key autophagy genes Atg5 or Atg7 using antisense compounds, including oligonucleotides, morpholinos, and shRNAs, administered intramuscularly and targeted to skeletal muscle, with specific sequences and conjugates disclosed.
Stated Advantages
Inhibition of autophagy enhances the effectiveness of enzyme replacement therapy in clearing glycogen from skeletal muscle in Pompe disease.
Suppression of autophagy alone results in diminished glycogen load in muscle fibers.
Combination of autophagy inhibition and enzyme replacement can normalize glycogen levels.
Improvement in lysosomal function is indicated by reduction of ubiquitinated proteins following combined treatment.
Muscle-specific suppression of autophagy does not result in major abnormalities in muscle function over observation periods.
Documented Applications
Treatment of lysosomal storage disorders, including Pompe disease, by inhibiting autophagy.
Adjunct treatment to enzyme replacement therapy for enhancing its efficacy in lysosomal storage disorders.
Use of antisense compounds, morpholino oligonucleotides, shRNAs, or small molecule inhibitors to inhibit essential autophagy genes in affected tissues such as skeletal muscle.
Screening and development of pharmaceutical agents that block autophagy using transgenic mouse models expressing fluorescent autophagosomal markers.
Generation of genetically modified animal models with knockouts of autophagy-related genes and lysosomal hydrolase genes to study the disease and therapeutic interventions.
Interested in licensing this patent?